文献速递前列腺癌

mTOR抑制剂在携带PI3K通路改变的转移性前列腺癌真实世界队列中的有效性与获益持久性

Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-11-19

本研究基于美国全国性去标识化前列腺癌临床基因组数据库,纳入17例经组织综合基因组分析确认携带PI3K通路改变的转移性前列腺癌患者,评估mTOR抑制剂治疗的临床有效性。结果显示PSA应答者少、治疗持续时间短,作者认为mTOR抑制剂治疗无效。

要点

  • 17例转移性前列腺癌患者中,15例(88.2%)接受依维莫司单药治疗。
  • 可评估PSA的10例中,仅2例在第12周PSA下降≥10%。
  • mTOR抑制剂治疗至下次治疗的中位时间为3.62个月(范围0,8.52)。

核心结论

  • 在这个携带组织评估PI3K通路改变的转移性前列腺癌小队列中,mTOR抑制剂治疗无效,PSA应答少且治疗持续时间短。

研究设计与样本

  • 回顾性研究,使用源自约280家美国癌症诊所(约800个诊疗点)的全国性去标识化前列腺癌临床基因组数据库,评估2014年10月至2020年2月的前列腺癌治疗数据。
  • 在2301例前列腺癌患者、7208个可评估治疗线中,选取17例经组织综合基因组分析确认携带PI3K通路改变并接受mTOR抑制剂治疗的转移性前列腺癌患者(2例激素敏感,15例去势抵抗)。

主要发现

  • 患者中位年龄72岁(IQR 68.0,76.0),mTOR抑制剂使用前中位接受过3线治疗(范围0-6)。
  • PI3K通路改变包括PTEN缺失10例(58.8%)、AKT1突变4例(23.5%)、PTEN突变2例(11.8%)、PTEN突变合并PIK3CA突变1例(5.9%)。
  • 15例(88.2%)接受依维莫司单药治疗。
  • 在10例有治疗中PSA数据的患者中,2例在第12周PSA下降≥10%,共5例随后出现PSA下降。
  • 接受mTOR抑制剂治疗的患者至下次治疗的中位时间为3.62个月(范围0,8.52)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称该队列为小队列(small cohort)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alterations in the PTEN/PI3K/AKT/mTOR pathway are prevalent in prostate cancer. In this retrospective study, we evaluated the clinical effectiveness of mTOR inhibitors (mTORi) in patients with metastatic prostate cancer (mPCA) and tissue assessed phosphatidyl-3-inositol kinase (PI3K) pathway alterations. METHODS: This study used a nationwide (US-based) de-identified PCA clinico-genomic database, originating from approximately 280 US cancer clinics (~800 sites of care). We evaluated treatment data for patients with PCA from October 2014 to February 2020. In a cohort of 2301 PCA patients with 7208 evaluable treatment lines, we selected 17 mPCA patients (2 hormone-sensitive, 15 castrate-resistant) with tissue assessed PI3K pathway alterations by comprehensive genomic profiling who received mTORi treatment. RESULTS: Patients had a median age of 72 years (IQR 68.0, 76.0) and were heavily pretreated with a median 3 lines of therapy prior to mTORi use (range 0-6). The PI3K pathway alterations included PTENdel (10 patients, 58.8%), AKT1mut (4 patients, 23.5%), PTENmut (2 patients, 11.8%), and dual PTENmut and PIK3CAmut (1 patient, 5.9%). Most (15 patients, 88.2%) were treated with everolimus monotherapy. Among 10 patients with on treatment PSA available, 2 patients had a PSA decrease ≥10% at week 12 and 5 patients overall had a subsequent PSA decrease. For those on mTORi, the median time to next treatment was 3.62 months (range 0, 8.52). CONCLUSIONS: In this small cohort of mPCA patients with tissue assessed PI3K pathway alterations, mTORi therapy was not effective with few PSA responses and short duration of therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Eule CJ, Flaig TW, Wong K, et al. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2022. PMID: 36402814. doi:10.1038/s41391-022-00612-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。